Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies

BACKGROUND/AIMS: Tofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo or tofacitinib 10 mg twice daily (BID) for 8 weeks. Clinical responders in OCTAV...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Intest Res
Main Authors: Motoya, Satoshi, Watanabe, Mamoru, Kim, Hyo Jong, Kim, Young Ho, Han, Dong Soo, Yuasa, Hirotoshi, Tabira, Junichi, Isogawa, Naoki, Arai, Shoko, Kawaguchi, Isao, Hibi, Toshifumi
פורמט: Artigo
שפה:Inglês
יצא לאור: Korean Association for the Study of Intestinal Diseases 2018
נושאים:
Original Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5934596/
https://ncbi.nlm.nih.gov/pubmed/29743836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2018.16.2.233
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים